U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. CPG Sec. 398.450 Applicability of Positive Beam Limitation (PBL) Requirements When PBL is Provided on "Other than Stationary General Purpose" Radiographic System
  1. Search for FDA Guidance Documents

COMPLIANCE POLICY GUIDE (CPG)

CPG Sec. 398.450 Applicability of Positive Beam Limitation (PBL) Requirements When PBL is Provided on "Other than Stationary General Purpose" Radiographic System August 1983

Final
Docket Number:
FDA-2020-D-0957
Issued by:
Guidance Issuing Office
Center for Devices and Radiological Health
Office of Regulatory Affairs

BACKGROUND:

According to the FDA Compliance Policy Guide No. 7133.11 (dated October 1, 1980) an x-ray system designed for and limited by its design for diagnostic purposes to only one of the following body regions is classified as "other than general purpose" for the purpose of Section 1020.31.

  1. Extremities
  2. Head and Neck
  3. Thoracic
  4. Abdominal

Some x-ray system manufacturers market other than general purpose systems with PBL even though it is not required. The question has been raised as to whether the PBL requirements of 1020.31(e)(2) would apply when PBL itself is not required.

POLICY:

A system in which the user depends on PBL rather than manual collimation creates an additional hazard if the PBL system does not function properly (especially if it oversizes the x-ray field). Therefore, when a radiographic system provides PBL operation, it must meet all requirements applicable to PBL systems, e.g., 1020.31(d)(1) and (2), and 1020.31(e)(1) and (2) even if PBL is not required. A system complying with the PBL requirements will be considered as complying with the requirements of 1020.31(f)(4).

Issued: 8/1/83

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2020-D-0957.

 
Back to Top